RU2020116571A - N4-гидроксицитидин и производные и связанные с этим противовирусные применения - Google Patents
N4-гидроксицитидин и производные и связанные с этим противовирусные применения Download PDFInfo
- Publication number
- RU2020116571A RU2020116571A RU2020116571A RU2020116571A RU2020116571A RU 2020116571 A RU2020116571 A RU 2020116571A RU 2020116571 A RU2020116571 A RU 2020116571A RU 2020116571 A RU2020116571 A RU 2020116571A RU 2020116571 A RU2020116571 A RU 2020116571A
- Authority
- RU
- Russia
- Prior art keywords
- virus
- pharmaceutically acceptable
- equine encephalitis
- compound
- coronavirus
- Prior art date
Links
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 241001502567 Chikungunya virus Species 0.000 claims 2
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 244000309467 Human Coronavirus Species 0.000 claims 2
- 241000712431 Influenza A virus Species 0.000 claims 2
- 241000713196 Influenza B virus Species 0.000 claims 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 2
- 241000712464 Orthomyxoviridae Species 0.000 claims 2
- 241000315672 SARS coronavirus Species 0.000 claims 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (16)
1. Фармацевтическая композиция, содержащая фармацевтически приемлемое вспомогательное вещество и соединение, выбранное из следующих:
2. Фармацевтическая композиция, содержащая фармацевтически приемлемое вспомогательное вещество и соединение, выбранное из следующих:
3. Фармацевтическая композиция, содержащая фармацевтически приемлемое вспомогательное вещество и соединение следующей структуры:
или его фармацевтически приемлемые или физиологические соли.
4. Фармацевтическая композиция, содержащая фармацевтически приемлемое вспомогательное вещество и соединение следующей структуры:
или его фармацевтически приемлемые или физиологические соли.
5. Способ лечения или предупреждения коронавируса человека, коронавируса SARS, коронавируса MERS, вируса восточного лошадиного энцефалита, вируса западного лошадиного энцефалита, вируса венесуэльского энцефалита лошадей, вируса чикунгунья и инфекции Росс-ривер, вируса Orthomyxoviridae или вируса Paramyxoviridae, или вируса RSV, или вируса гриппа A и вируса гриппа B, или вируса Filoviridae, или инфекции вируса Эбола у пациента, включающий введение пациенту, нуждающемуся в этом, эффективного количества соединения структуры
или его фармацевтически приемлемых или физиологических солей.
6. Способ лечения или предупреждения коронавируса человека, коронавируса SARS, коронавируса MERS, вируса восточного лошадиного энцефалита, вируса западного лошадиного энцефалита, вируса венесуэльского энцефалита лошадей, вируса чикунгунья и инфекции Росс-ривер, вируса Orthomyxoviridae или вируса Paramyxoviridae, или вируса RSV, или вируса гриппа A и вируса гриппа B, или вируса Filoviridae, или инфекции вируса Эбола у пациента, включающий введение пациенту, нуждающемуся в этом, эффективного количества соединения структуры
или его фармацевтически приемлемых или физиологических солей.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762595907P | 2017-12-07 | 2017-12-07 | |
US62/595,907 | 2017-12-07 | ||
US201862626998P | 2018-02-06 | 2018-02-06 | |
US62/626,998 | 2018-02-06 | ||
US201862760434P | 2018-11-13 | 2018-11-13 | |
US62/760,434 | 2018-11-13 | ||
PCT/US2018/064503 WO2019113462A1 (en) | 2017-12-07 | 2018-12-07 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2023133687A Division RU2023133687A (ru) | 2017-12-07 | 2018-12-07 | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2020116571A true RU2020116571A (ru) | 2021-11-22 |
RU2020116571A3 RU2020116571A3 (ru) | 2021-11-22 |
Family
ID=66751806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020116571A RU2020116571A (ru) | 2017-12-07 | 2018-12-07 | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
Country Status (16)
Country | Link |
---|---|
US (2) | US11331331B2 (ru) |
EP (1) | EP3706762A4 (ru) |
JP (4) | JP6804790B1 (ru) |
KR (3) | KR20240011880A (ru) |
CN (1) | CN111372592A (ru) |
AU (2) | AU2018378832B9 (ru) |
BR (2) | BR122022008466B1 (ru) |
CA (1) | CA3082191C (ru) |
GB (2) | GB2581936B (ru) |
IL (2) | IL274155B (ru) |
MX (2) | MX2020005392A (ru) |
PH (1) | PH12020550607A1 (ru) |
RU (1) | RU2020116571A (ru) |
SG (1) | SG11202004403QA (ru) |
WO (1) | WO2019113462A1 (ru) |
ZA (1) | ZA202002849B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2791806C1 (ru) * | 2022-12-28 | 2023-03-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Применение 5'-О-(3-фенилпропионил)-N4-гидроксицитидина для ингибирования репликации вируса гриппа in vitro и in vivo |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201705069YA (en) * | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3706762A4 (en) * | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
CN112390838A (zh) * | 2019-08-14 | 2021-02-23 | 斯微(上海)生物科技有限公司 | 一种改性核苷及其合成方法 |
AU2020346908A1 (en) * | 2019-09-11 | 2022-03-24 | The Scripps Research Institute | Antiviral prodrugs and formulations thereof |
PE20230466A1 (es) * | 2020-02-07 | 2023-03-14 | Univ Emory | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos |
CN111285911B (zh) * | 2020-02-26 | 2021-04-02 | 山东大学 | Gem-1mt两亲小分子化合物及其制剂、制备方法和应用 |
AU2021260040A1 (en) | 2020-04-21 | 2022-11-17 | Immunic Ag | Vidofludimus for use in the treatment or prevention of viral diseases |
WO2022047229A1 (en) * | 2020-08-27 | 2022-03-03 | Emory University | Novel forms of antiviral nucleosides |
US11702440B2 (en) * | 2020-12-10 | 2023-07-18 | Optimus Drugs Private Limited | Pharmaceutical polymorphs of Molnupiravir |
KR20230121622A (ko) * | 2020-12-18 | 2023-08-18 | 머크 샤프 앤드 돔 엘엘씨 | 항바이러스 뉴클레오시드의 합성 |
CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
CN112778387A (zh) * | 2021-01-15 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种Molnupiravir晶型A及其制备方法 |
WO2022168107A1 (en) * | 2021-02-06 | 2022-08-11 | Fermenta Biotech Limited | Enzymatic synthesis of molnupiravir intermediate |
WO2022168106A1 (en) * | 2021-02-06 | 2022-08-11 | Fermenta Biotech Limited | Chemo-enzymatic process for synthesis of molnupiravir |
CN112552288A (zh) * | 2021-02-19 | 2021-03-26 | 南京桦冠生物技术有限公司 | 一种4-肟-5`-(2-甲基丙酰基)尿苷的制备方法 |
CN113072606A (zh) * | 2021-03-18 | 2021-07-06 | 南京正济医药研究有限公司 | 一种n4-羟基胞苷类化合物的晶型及其制备方法与用途 |
US11312743B1 (en) * | 2021-03-20 | 2022-04-26 | Optimus Drugs Private Limited | Process for molnupiravir |
WO2022208156A1 (en) * | 2021-03-29 | 2022-10-06 | Optimus Pharma Private Limited | Pharmaceutical composition of molnupiravir |
WO2022214691A1 (en) | 2021-04-09 | 2022-10-13 | Immunic Ag | Deuterated dhodh inhibitors |
CN115215914A (zh) * | 2021-04-15 | 2022-10-21 | 中国科学院上海药物研究所 | 核苷类似物及其用途 |
CN113307834A (zh) * | 2021-04-23 | 2021-08-27 | 安徽贝克联合制药有限公司 | 一种核糖核苷类似物的多晶型物、其制备方法及应用 |
US11407779B1 (en) | 2021-04-23 | 2022-08-09 | Divi's Laboratories Ltd. | Process for the preparation of molnupiravir |
CN113278040B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | 5’-异丁酰基-n4-羟基胞苷的制备方法 |
CN117642410A (zh) * | 2021-06-18 | 2024-03-01 | 苏州春海生物医药有限公司 | N4-羟基胞苷的酯衍生物及其用途 |
CN113321694A (zh) * | 2021-06-22 | 2021-08-31 | 药康众拓(江苏)医药科技有限公司 | N4-羟基胞苷衍生物及其制备方法和用途 |
CN113433242B (zh) * | 2021-06-28 | 2022-12-27 | 成都大学 | Molnupiravir含量及有关物质的检测方法 |
CN113278041B (zh) * | 2021-07-16 | 2021-10-19 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用 |
CN113735929A (zh) * | 2021-07-21 | 2021-12-03 | 海化生命(厦门)科技有限公司 | 一种抗冠状病毒的化合物及其制备方法与应用 |
WO2023012329A1 (en) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Method of treating veterinary viral diseases |
CN115960148B (zh) * | 2021-08-27 | 2023-12-12 | 南京知和医药科技有限公司 | 一种新型的胞苷衍生物及其药物组合物和用途 |
WO2023068287A1 (ja) * | 2021-10-19 | 2023-04-27 | 興和株式会社 | 新規医薬 |
WO2023067623A1 (en) * | 2021-10-20 | 2023-04-27 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | A short and cost effective synthetic route towards anti viral eidd-1931 and its hydrate polymorphs |
CN114085259A (zh) * | 2021-10-21 | 2022-02-25 | 苏州立新制药有限公司 | N4-羟基胞苷一水合物及其晶型b与制备方法和用途 |
CN113880902A (zh) * | 2021-10-26 | 2022-01-04 | 江苏睿实生物科技有限公司 | 一种Molnupiravir药物中间体及其制备方法 |
WO2023073239A1 (en) | 2021-11-01 | 2023-05-04 | Immunic Ag | Medical use of n4-hydroxy citicoline compounds |
CN113929724A (zh) * | 2021-11-02 | 2022-01-14 | 周雨恬 | 一种核苷类化合物及其药物组合物和用途 |
CN114306254B (zh) * | 2021-11-30 | 2023-11-03 | 南京正济医药研究有限公司 | 一种Molnupiravir口服固体制剂及其制备方法 |
CN116217632A (zh) * | 2021-12-06 | 2023-06-06 | 广州谷森制药有限公司 | 一种氘代胞苷衍生物的制备方法 |
WO2023111683A1 (en) * | 2021-12-16 | 2023-06-22 | Ascletis Bioscience Co., Ltd. | N4-hydroxycytidine derivatives and use thereof as antiviral agent |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
TW202332433A (zh) | 2021-12-23 | 2023-08-16 | 德商埃慕尼克股份公司 | 含羧酸生物電子等排體之dhodh抑制劑 |
WO2023118896A1 (en) | 2021-12-23 | 2023-06-29 | Subintro Limited | Novel antiviral compositions comprising oleic acid |
CN114507266A (zh) * | 2022-01-24 | 2022-05-17 | 海门品尚医药科技有限公司 | 一种Molnupiravir晶型及其制备方法 |
CN114560894B (zh) * | 2022-03-11 | 2023-06-20 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Molnupiravir的制备方法 |
CN114773405B (zh) * | 2022-06-21 | 2022-09-23 | 和鼎(南京)医药技术有限公司 | 一种莫那比拉韦的制备方法 |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1325798A (en) | 1970-09-24 | 1973-08-08 | Upjohn Co | Derivatives of 2,2-anhydro-ara-cytidine |
GB1386334A (en) | 1972-09-22 | 1975-03-05 | Kohjin Co | 2,2-cyclocytidine derivatives |
DE2456547A1 (de) | 1973-11-29 | 1975-08-14 | Kohjin Co | N hoch 4 -substituierte 2,2'-cyclocytidin-verbindungen |
US4096324A (en) | 1975-07-07 | 1978-06-20 | The Upjohn Company | Cytidine nucleoside compound |
US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
CA2058632C (en) | 1989-06-05 | 2004-08-24 | Brian C. Froehler | Exonuclease-resistant oligonucleotides and methods for preparing the same |
EP0558634A4 (en) | 1990-11-23 | 1995-06-28 | Gilead Sciences Inc | Triplex-forming oligomers containing modified bases |
FI105556B (fi) | 1991-09-30 | 2000-09-15 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta |
AU661347B2 (en) | 1991-10-11 | 1995-07-20 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives |
DE637965T1 (de) | 1991-11-26 | 1995-12-14 | Gilead Sciences Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen. |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
AU6632094A (en) | 1993-04-19 | 1994-11-08 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5349947A (en) | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
AU690587B2 (en) | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
BR9407510A (pt) | 1993-09-17 | 1997-01-07 | Gilead Sciences Inc | Análogos de nucleotideo |
HU228450B1 (en) | 1995-02-27 | 2013-03-28 | Gilead Sciences Inc | Novel selective inhibitors of viral or bacterial neuraminidases |
US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
KR20000052702A (ko) | 1996-10-21 | 2000-08-25 | 헨슬레이 맥스 디. | 피페리딘 화합물 |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6086376A (en) | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
BR0114837A (pt) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
CA2743451A1 (en) * | 2000-10-18 | 2002-04-25 | Pharmasset, Inc. | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
NZ575481A (en) | 2000-10-18 | 2010-10-29 | Pharmasset Inc | Simultaneous quantification of nucleic acids in diseased cells |
ES2327397T3 (es) | 2001-04-30 | 2009-10-29 | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL | Esteres de uridina farmaceuticamente activos. |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US7049303B2 (en) | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
EA200401437A1 (ru) | 2002-04-26 | 2005-04-28 | Джилид Сайэнс, Инк. | Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам |
US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
WO2004006843A2 (en) | 2002-07-15 | 2004-01-22 | Gilead Sciences, Inc. | Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
EP1541174A4 (en) | 2002-09-11 | 2005-09-14 | Michio Ishibashi | MEDICINE OR COSMETIC PRODUCT |
EP1546190A2 (en) | 2002-10-01 | 2005-06-29 | Gilead Sciences, Inc. | Hbv mutations associated with reduced susceptibility to adefovir |
AU2003301439A1 (en) | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
AU2003287606A1 (en) | 2002-11-12 | 2004-06-03 | Enzon Pharmaceuticals, Inc. | Novel acylating reagents |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
EP1581496A4 (en) | 2002-12-02 | 2008-04-23 | Gilead Sciences Inc | 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION |
EP3025718A1 (en) | 2003-01-14 | 2016-06-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
CN101410120A (zh) | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
MXPA05011294A (es) | 2003-04-25 | 2006-03-15 | Gilead Sciences Inc | Compuestos de fosfonato anti-inflamatorios. |
DK1628685T3 (da) | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antivirale phosphonatanaloge |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7579332B2 (en) | 2003-07-30 | 2009-08-25 | Gilead Sciences, Inc. | Nucleobase phosphonate analogs for antiviral treatment |
WO2005028478A1 (en) | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Aza-quinolinol phosphonate integrase inhibitor compounds |
RU2264409C2 (ru) | 2003-10-01 | 2005-11-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") | 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург |
AU2004290298A1 (en) | 2003-10-24 | 2005-05-26 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
US20070160554A1 (en) | 2003-11-03 | 2007-07-12 | Cognis Ip Management Gmbh | Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same |
ATE544765T1 (de) | 2003-12-22 | 2012-02-15 | Leuven K U Res & Dev | Imidazoä4,5-cüpyridinverbindungen und verfahren zur antiviralen behandlung |
US20080287471A1 (en) | 2003-12-22 | 2008-11-20 | Maria Fardis | 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity |
CN1950383B (zh) | 2003-12-30 | 2010-06-09 | 吉里德科学公司 | 用于治疗病毒性疾病的膦酸酯、单膦酸酰胺化物、双膦酸酰胺化物 |
EP1711476A2 (en) | 2004-01-12 | 2006-10-18 | Gilead Sciences, Inc. | Pyrimidyl phosphonate antiviral compounds and methods of use |
ES2334149T3 (es) | 2004-01-21 | 2010-03-05 | Gilead Sciences, Inc. | Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. |
CA2562713A1 (en) | 2004-04-14 | 2005-12-15 | Gilead Sciences, Inc. | Phosphonate analogs of hiv integrase inhibitor compounds |
UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
AR050174A1 (es) | 2004-07-16 | 2006-10-04 | Gilead Sciences Inc | Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas |
KR101238430B1 (ko) | 2004-07-27 | 2013-02-28 | 길리애드 사이언시즈, 인코포레이티드 | 이미다조[4,5-d]피리미딘, 그들의 용도 및 제조방법 |
HUE043207T2 (hu) | 2004-07-27 | 2019-08-28 | Gilead Sciences Inc | HIV-gátló vegyületek foszfonát analógjai |
DE102004051804A1 (de) * | 2004-10-21 | 2006-04-27 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen |
WO2006047661A2 (en) | 2004-10-26 | 2006-05-04 | Gilead Sciences, Inc. | Phosphonate derivatives of mycophenolic acid |
CA2592388C (en) | 2004-12-21 | 2013-04-02 | Steven S. Bondy | Imidazo[4,5-c]pyridine compound and method of antiviral treatment |
WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
JP5461009B2 (ja) | 2005-06-08 | 2014-04-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 非ペプチド及びペプチドbdnfニューロトロフィン類似体を用いた神経細胞生存促進法 |
TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
US20070128625A1 (en) | 2005-07-25 | 2007-06-07 | Gilead Sciences, Llc | Drug-resistant mutants of hepatitis C virus |
CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
JP5016601B2 (ja) | 2005-08-16 | 2012-09-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
ES2317583T3 (es) | 2005-09-22 | 2009-04-16 | F. Hoffmann-La Roche Ag | O-acilacion selectiva de nucleosidos. |
SG170796A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2007245194B2 (en) | 2006-03-29 | 2013-03-14 | Gilead Sciences, Inc. | Process for preparation of HIV protease inhibitors |
US20090318456A1 (en) | 2006-07-06 | 2009-12-24 | Gilead Sciences, Inc. | Substituted pteridines for the treatment and prevention of viral infections |
TWI411613B (zh) | 2006-07-07 | 2013-10-11 | Gilead Sciences Inc | 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑 |
ES2339298T3 (es) | 2006-07-07 | 2010-05-18 | Gilead Sciences, Inc. | Compuesto de piridazina novedoso y uso del mismo. |
DK2038290T3 (da) | 2006-07-07 | 2013-12-02 | Gilead Sciences Inc | Modulatorer af toll-lignende receptor 7 |
WO2008005542A2 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
AU2007275689A1 (en) | 2006-07-21 | 2008-01-24 | Gilead Sciences, Inc. | AZA-peptide protease inhibitors |
EP2069303B1 (en) | 2006-07-21 | 2016-03-30 | Gilead Sciences, Inc. | Antiviral protease inhibitors |
CN101495461A (zh) | 2006-07-24 | 2009-07-29 | 吉里德科学公司 | 新的hiv逆转录酶抑制剂 |
EP2069356A1 (en) | 2006-07-24 | 2009-06-17 | Gilead Sciences, Inc. | Bisfuranyl protease inhibitors |
US20100189772A1 (en) | 2006-09-27 | 2010-07-29 | Coley Pharmaceutical Group, Inc | Compositions of TLR ligands and antivirals |
US8263612B2 (en) | 2006-12-14 | 2012-09-11 | Gilead Sciences, Inc. | Viral inhibitors |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US8637531B2 (en) | 2006-12-26 | 2014-01-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyridmidines useful for treating viral infections |
WO2008077649A1 (en) | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infectons |
WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
WO2008119659A2 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Pharmaceutical composition and process |
US8354421B2 (en) | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
TW200918507A (en) | 2007-06-29 | 2009-05-01 | Gilead Sciences Inc | Novel HIV reverse transcriptase inhibitors |
US8513186B2 (en) | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
MX2009013832A (es) | 2007-06-29 | 2010-03-10 | Gilead Sciences Inc | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. |
AR067183A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Composiciones terapeuticas y metodos, usos y equipos |
AR067180A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
EP2162431B1 (en) | 2007-06-29 | 2017-06-07 | Gilead Sciences, Inc. | Antiviral compounds |
KR20100028656A (ko) | 2007-06-29 | 2010-03-12 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
WO2009058800A2 (en) | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
EP2234623A4 (en) | 2007-12-27 | 2012-03-28 | Epiphany Biosciences | ANTIVIRAL CONNECTIONS |
CA2710679A1 (en) | 2008-01-04 | 2009-07-16 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
WO2009132135A1 (en) | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | 1' -substituted carba-nucleoside analogs for antiviral treatment |
WO2009143011A1 (en) | 2008-05-20 | 2009-11-26 | Novartis Ag | Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
WO2010002998A1 (en) | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
US20100093667A1 (en) | 2008-07-08 | 2010-04-15 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
US7998950B2 (en) | 2008-07-25 | 2011-08-16 | Gilead Sciences, Inc. | Antiviral compounds |
EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
EP2379579A1 (en) | 2008-12-19 | 2011-10-26 | Gilead Sciences, Inc. | Hcv ns3 protease inhibitors |
JP2012513397A (ja) | 2008-12-22 | 2012-06-14 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス化合物 |
CA2751277C (en) | 2009-02-10 | 2018-10-30 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
RS55249B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
AR077139A1 (es) | 2009-06-23 | 2011-08-03 | Gilead Sciences Inc | Composiciones farmaceuticas utiles para tratar el vch |
UY32715A (es) | 2009-06-23 | 2011-01-31 | Gilead Sciences Inc | Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados |
US20100324059A1 (en) | 2009-06-23 | 2010-12-23 | Gilead Sciences, Inc. | Pharmaceutical compositions useful for treating hcv |
WO2011005842A1 (en) | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
SG177709A1 (en) | 2009-07-21 | 2012-02-28 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
PT2507249E (pt) | 2009-09-09 | 2016-02-15 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
NO2477987T3 (ru) | 2009-09-14 | 2018-06-09 | ||
NZ599402A (en) | 2009-09-21 | 2014-02-28 | Gilead Sciences Inc | 2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
JP5694345B2 (ja) | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体の調節因子 |
WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
EP3219713A1 (en) | 2010-01-15 | 2017-09-20 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
PT2523951E (pt) | 2010-01-15 | 2015-09-14 | Gilead Sciences Inc | Inibidores de vírus flaviviridae |
CN102725303B (zh) * | 2010-01-28 | 2015-05-27 | 里博科学有限责任公司 | 作为抗hcv化合物的4’-叠氮基-核苷 |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
AR081026A1 (es) | 2010-05-10 | 2012-05-30 | Gilead Sciences Inc | Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias |
US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
EP2571882A1 (en) | 2010-05-21 | 2013-03-27 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
TW201210597A (en) | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
WO2011156757A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
ES2551738T3 (es) | 2010-06-11 | 2015-11-23 | Gilead Sciences, Inc. | Formulaciones tópicas antivirales para la prevención de la transmisión del VHS-2 |
EA201591390A1 (ru) | 2010-06-24 | 2016-06-30 | Джилид Сайэнс, Инк. | Пиразол[1,5-a]пиримидины для противовирусного лечения |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
CA2802308C (en) | 2010-07-02 | 2018-08-28 | Lianhong Xu | Napht-2-ylacetic acid derivatives to treat aids |
BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
CR20170278A (es) | 2010-07-22 | 2017-09-29 | Gilead Sciences Inc | Métodos y compuestos para tratar infecciones virales por paramyxoviridae |
CN102351931B (zh) | 2010-09-07 | 2014-01-22 | 河南省科学院高新技术研究中心 | 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用 |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
KR101879887B1 (ko) | 2010-09-20 | 2018-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체 |
KR101835474B1 (ko) | 2010-11-17 | 2018-03-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
BR112013012245B1 (pt) | 2010-11-19 | 2022-09-27 | Janssen Sciences Ireland Uc | Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv |
UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
CA2822037A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
WO2012088153A1 (en) | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
WO2012088156A1 (en) | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
US20130274254A1 (en) | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
TW201302761A (zh) | 2011-04-04 | 2013-01-16 | Gilead Sciences Inc | Hiv抑制劑之固態形式 |
JP2014511859A (ja) | 2011-04-04 | 2014-05-19 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤の調製のためのプロセス |
WO2012142523A2 (en) | 2011-04-13 | 2012-10-18 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
PT2705027E (pt) | 2011-05-02 | 2015-09-11 | Gilead Sciences Inc | Sais sólido de amorfo de cobicistat (gs-9350) |
JP6205354B2 (ja) | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ, インコーポレイテッド | Hivの処置のための化合物 |
CA2840868A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Hcv genotype 4 replicons |
US8889848B2 (en) | 2011-07-06 | 2014-11-18 | Gilead Sciences, Inc. | HCV genotype 3 replicons |
WO2013010112A1 (en) | 2011-07-13 | 2013-01-17 | Gilead Sciences, Inc. | Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses |
UA115311C2 (uk) | 2011-08-16 | 2017-10-25 | Гіліад Сайєнсіз, Інк. | Геміфумарат тенофовіру алафенаміду |
SG10201602044WA (en) | 2011-09-16 | 2016-04-28 | Gilead Pharmassett Llc | Methods For Treating HCV |
WO2013066748A1 (en) | 2011-10-31 | 2013-05-10 | Gilead Pharmasset Llc | Methods and compositions for treating hepatitis c virus |
PE20171444A1 (es) | 2011-11-16 | 2017-09-29 | Gilead Pharmasset Llc | Compuestos antivirales |
MX2014006373A (es) | 2011-11-29 | 2014-07-22 | Gilead Pharmasset Llc | Composiciones y metodos para tratar el virus de la hepatitis c. |
WO2013090840A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
WO2013090929A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | Amino quinoline derivatives inhibitors of hcv |
CA2858090A1 (en) | 2011-12-20 | 2013-06-27 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders |
SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
EP2794611B1 (en) | 2011-12-22 | 2017-10-11 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
US20150004239A1 (en) | 2012-01-12 | 2015-01-01 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
WO2013115916A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
BR112014018918A8 (pt) | 2012-02-03 | 2017-07-11 | Gilead Sciences Inc | Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais |
EP3351552B1 (en) | 2012-03-13 | 2021-05-19 | Gilead Sciences, Inc. | 2'-substituted carba-nucleoside analogs for antiviral treatment |
CN104203253A (zh) | 2012-03-21 | 2014-12-10 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
CN106986869A (zh) | 2012-04-17 | 2017-07-28 | 吉利德科学公司 | 用于抗病毒治疗的化合物和方法 |
MD20140063A2 (ru) | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Производные бензотиазол-6-ил уксусной кислоты и их применение для лечения инфекции ВИЧ |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
NZ724616A (en) | 2012-06-08 | 2018-06-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
SG11201408047XA (en) | 2012-06-08 | 2015-01-29 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
WO2014064588A2 (en) | 2012-10-26 | 2014-05-01 | Koninklijke Philips N.V. | Autostereoscopic display device having a see-through mode of operation. |
CN104884462A (zh) | 2012-10-29 | 2015-09-02 | 共晶制药股份有限公司 | 用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药 |
US20140120102A1 (en) | 2012-10-30 | 2014-05-01 | Gilead Sciences, Inc. | Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) |
CA2890277A1 (en) | 2012-11-07 | 2014-05-15 | Gilead Sciences, Inc. | Hcv genotype 6 replicons |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
AU2014205317B2 (en) | 2013-01-09 | 2016-11-24 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
WO2014124430A1 (en) | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
TWI706945B (zh) | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ, インコーポレイテッド | C型肝炎ウイルスの大環状二環式阻害剤 |
US20140273023A1 (en) | 2013-03-15 | 2014-09-18 | Saladax Biomedical Inc. | Gemcitabine immunoassay |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
BR112015025716A2 (pt) | 2013-04-12 | 2017-07-18 | Achillion Pharmaceuticals Inc | pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv |
MY186547A (en) | 2013-05-16 | 2021-07-26 | Riboscience Llc | 4?-fluoro-2?-methyl substituted nucleoside derivatives |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
US20150072418A1 (en) | 2013-08-16 | 2015-03-12 | Gilead Sciences, Inc. | Hcv genotype 4d replicons |
ES2927955T3 (es) | 2013-09-11 | 2022-11-14 | Univ Emory | Composiciones de nucleótidos y nucleósidos y sus usos |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
US20150150897A1 (en) | 2013-12-02 | 2015-06-04 | Gilead Pharmasset Llc | Methods of treating hepatitis c virus infection in subjects with cirrhosis |
EP3087086B1 (en) | 2013-12-23 | 2018-11-07 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
US9463194B2 (en) | 2014-02-05 | 2016-10-11 | Gilead Sciences, Inc. | Methods of treating patients co-infected with HIV and tuberculosis |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
WO2015179448A1 (en) | 2014-05-21 | 2015-11-26 | Gilead Sciences, Inc. | Therapeutic compounds |
AU2015274863B2 (en) | 2014-06-12 | 2018-03-22 | Gilead Sciences, Inc. | Antiviral compounds |
EA201692249A1 (ru) | 2014-06-13 | 2017-05-31 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
ES2763104T3 (es) | 2014-06-13 | 2020-05-27 | Gilead Sciences Inc | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-quinasa |
AU2015274637B2 (en) | 2014-06-13 | 2018-04-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
CN106660994A (zh) | 2014-06-13 | 2017-05-10 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
EP3154960A1 (en) | 2014-06-13 | 2017-04-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
DK3160476T3 (da) | 2014-06-24 | 2020-12-21 | Janssen Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner |
EP3160475B1 (en) | 2014-06-24 | 2024-01-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides and nucleotides to treat filoviridae infections |
CN105288635A (zh) | 2014-06-26 | 2016-02-03 | 昆明积大制药股份有限公司 | 一种含有阿糖胞苷5’-0-氨基酸酯的药物组合物 |
NZ728072A (en) | 2014-07-11 | 2018-06-29 | Gilead Sciences Inc | Modulators of toll-like receptors for the treatment of hiv |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | 2’-氯胺基嘧啶酮及嘧啶二酮核苷類 |
NZ729150A (en) | 2014-08-29 | 2018-02-23 | Gilead Sciences Inc | Antiretroviral agents |
WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
NZ733135A (en) | 2014-12-24 | 2018-06-29 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
SG11201705069YA (en) * | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2016134054A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
KR101756050B1 (ko) | 2015-03-04 | 2017-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
AU2016244035B2 (en) | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2016168349A1 (en) | 2015-04-14 | 2016-10-20 | Gilead Sciences, Inc. | Methods of treating hepatitis b virus |
ES2761824T3 (es) | 2015-05-15 | 2020-05-21 | Gilead Sciences Inc | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa |
CA2987085A1 (en) | 2015-06-17 | 2016-12-22 | Gilead Sciences, Inc. | Co-crystals, salts and solid forms of tenofovir alafenamide |
PT3607939T (pt) | 2015-06-30 | 2022-09-12 | Gilead Sciences Inc | Formulações farmacêuticas compreendendo tenofovir e emtricitabina |
CA2921336A1 (en) | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
AU2016301188A1 (en) | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017040896A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
WO2017040895A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
EP3349757A1 (en) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
SG10202001878WA (en) | 2015-09-16 | 2020-04-29 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
WO2017059120A1 (en) | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
EP3632415A1 (en) | 2015-11-09 | 2020-04-08 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
CN108430993A (zh) | 2015-12-17 | 2018-08-21 | 吉利德科学公司 | Tank-结合激酶抑制剂化合物 |
WO2017156380A1 (en) | 2016-03-10 | 2017-09-14 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2017165489A1 (en) * | 2016-03-23 | 2017-09-28 | Emory University | Antiviral agents for treating zika and dengue virus infections |
PL3377637T3 (pl) | 2016-04-08 | 2020-09-07 | Krystal Biotech, Inc. | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry |
WO2017184668A1 (en) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating flaviviridae virus infections |
WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
KR102202984B1 (ko) | 2016-05-27 | 2021-01-13 | 길리애드 사이언시즈, 인코포레이티드 | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
EP3471738A4 (en) | 2016-06-20 | 2020-01-01 | Merck Sharp & Dohme Corp. | PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES |
WO2017223268A1 (en) | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
EP3706762A4 (en) * | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
CN112074506A (zh) | 2018-03-07 | 2020-12-11 | 埃默里大学 | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
PE20230466A1 (es) | 2020-02-07 | 2023-03-14 | Univ Emory | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos |
-
2018
- 2018-12-07 EP EP18886104.1A patent/EP3706762A4/en active Pending
- 2018-12-07 KR KR1020247001358A patent/KR20240011880A/ko active Application Filing
- 2018-12-07 KR KR1020207014737A patent/KR102248165B1/ko active IP Right Grant
- 2018-12-07 CA CA3082191A patent/CA3082191C/en active Active
- 2018-12-07 BR BR122022008466-4A patent/BR122022008466B1/pt active IP Right Grant
- 2018-12-07 AU AU2018378832A patent/AU2018378832B9/en active Active
- 2018-12-07 GB GB2008628.6A patent/GB2581936B/en active Active
- 2018-12-07 CN CN201880073278.8A patent/CN111372592A/zh active Pending
- 2018-12-07 KR KR1020217012910A patent/KR102626210B1/ko active IP Right Grant
- 2018-12-07 US US16/755,779 patent/US11331331B2/en active Active
- 2018-12-07 MX MX2020005392A patent/MX2020005392A/es unknown
- 2018-12-07 RU RU2020116571A patent/RU2020116571A/ru unknown
- 2018-12-07 SG SG11202004403QA patent/SG11202004403QA/en unknown
- 2018-12-07 JP JP2020524817A patent/JP6804790B1/ja active Active
- 2018-12-07 BR BR112020010581-3A patent/BR112020010581A2/pt not_active Application Discontinuation
- 2018-12-07 GB GB2020498.8A patent/GB2590198B/en active Active
- 2018-12-07 WO PCT/US2018/064503 patent/WO2019113462A1/en active Application Filing
-
2020
- 2020-04-22 IL IL274155A patent/IL274155B/en unknown
- 2020-05-08 PH PH12020550607A patent/PH12020550607A1/en unknown
- 2020-05-15 ZA ZA2020/02849A patent/ZA202002849B/en unknown
- 2020-07-13 MX MX2023008882A patent/MX2023008882A/es unknown
- 2020-11-26 JP JP2020195927A patent/JP7179372B2/ja active Active
-
2021
- 2021-06-16 IL IL284100A patent/IL284100A/en unknown
- 2021-06-28 JP JP2021106296A patent/JP7305205B2/ja active Active
- 2021-07-22 AU AU2021206866A patent/AU2021206866B2/en active Active
- 2021-09-02 US US17/465,344 patent/US11903959B2/en active Active
-
2023
- 2023-04-07 JP JP2023062657A patent/JP2023082213A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2791806C1 (ru) * | 2022-12-28 | 2023-03-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Применение 5'-О-(3-фенилпропионил)-N4-гидроксицитидина для ингибирования репликации вируса гриппа in vitro и in vivo |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2020116571A (ru) | N4-гидроксицитидин и производные и связанные с этим противовирусные применения | |
HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
JP2016508134A5 (ru) | ||
CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
CY1114089T1 (el) | Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278 | |
EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
JP2017502074A5 (ru) | ||
CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
PH12019550039A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
RU2016114098A (ru) | Новое производное аналога инсулина | |
WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
BR112022000971A2 (pt) | Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
JP2012097034A5 (ru) | ||
MX2022001266A (es) | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
JP2010519274A5 (ru) | ||
PH12020500001A1 (en) | Non-pulsatile prolonged-release betahistine oral solid compositions | |
Morozov et al. | EFFECTIVENESS OF UNIVERSAL SYSTEM BIOACTIVE THE BONDING AT TREATMENT OF CARIES | |
RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |